Systemic Lupus Erythematosus in Gullah Health

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Healthy Volunteers: t
View:

• Age 2 years and above;

• Self-identified as African-American Gullah from the Sea Island region of South Carolina;

• Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control;

• Ability to speak and understand English;

• Ability and willingness to give informed consent

Locations
United States
South Carolina
Medical University of South Carolina
RECRUITING
Charleston
Contact Information
Primary
Diane L. Kamen, MD, MSCR
kamend@musc.edu
843-792-4825
Time Frame
Start Date: 2003-04
Estimated Completion Date: 2028-06
Participants
Target number of participants: 750
Treatments
1
Patients with SLE
2
Related unaffected controls
3
Unrelated unaffected controls
Related Therapeutic Areas
Sponsors
Leads: Medical University of South Carolina
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

This content was sourced from clinicaltrials.gov